ArticleHealth and quality of life outcomes2025
Evaluation of measurement properties of the Health Assessment Questionnaire-Disability Index (HAQ-DI) among gout patients in China.
Article in Health and quality of life outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo evaluate measurement properties of Chinese version of the Health Assessment Questionnaire Disability Index (HAQ-DI) among Chinese gout patients.
methodA representative sample of Chinese gout patients were recruited with stratification based on age, sex, urban/rural residence, and education level. Ceiling and floor effects were evaluated. Reliability was assessed by internal consistency (Cronbach’s α). Structural validity was verified by confirmatory factor analysis (CFA). Convergent validity was assessed using Spearman’s rank coefficient, examining the correlation between the HAQ-DI and EQ-5D-5L. Known-groups validity was evaluated by determining the HAQ-DI score differences between subgroup patients. Effect sizes were then used to assess sensitivity of the subgroup differences.
resultsA total of 1,000 patients were included in the study. Ceiling and floor effects were both not observed. Cronbach’s α was 0.95. The factor loadings of CFA were all above 0.6 and the model fit indices were acceptable (χ2/df = 5.97, RMSEA = 0.071, RFI = 0.906, CFI = 0.940, TLI = 0.920), indicating that the eight-factor model had well structural validity. The HAQ-DI correlated in predictable ways with five EQ-5D-5L dimensions, with Spearman’s rank coefficient ranging from 0.30 to 0.61. The HAQ-DI can discriminate between subgroup patients with different levels of health status, with the mean effect size (0.73) at a medium level.
conclusionsChinese version of the HAQ-DI was verified to have satisfactory reliability, validity, and sensitivity in measuring health-related quality of life of Chinese gout patients. We recommend supplementing the responsiveness of the HAQ-DI to changes over time in future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.